Search

Displaying results 3581 - 3590 of 7018 in total
  1. Drug

    Zanapezil

    go.drugbank.com/drugs/DB04859
    Experimental

    Zanapezil (TAK-147) is a selective acetylcholine (ACh) esterase inhibitor under investigation as a drug for Alzheimer's disease (AD) treatment.

  2. Drug

    GFT14

    go.drugbank.com/drugs/DB05061
    Experimental

    GFT14 is destined to improve the condition of patients at risk from cardiovascular disease by a simultaneous and favorable action on the plasmatic lipids (rise of HDL- cholesterol et lowering of triglycerides … ) and on other risk factors such as hypertension or diabetes.

  3. Drug

    Mephenesin

    go.drugbank.com/drugs/DB13583
    ApprovedWithdrawn

    Mephenesin is a synthetic cresol glyceryl ether which produces transient muscle relaxation and paralysis via central nervous system depression [A32760]. It first entered use in the 1950s.

  4. Drug

    Fiztasovimab

    go.drugbank.com/drugs/DB24033
    Investigational

    [A278004, A278005] NPC-21 is under investigation in clinical trial NCT04225923 (A Study for Kidney Transplant Recipients at High-Risk of Cytomegalovirus Infection). … Fiztasovimab, also known as NPC‐21 and EV2038, is a monoclonal antibody.

  5. Drug

    Nelfinavir

    go.drugbank.com/drugs/DB00220
    ApprovedInvestigational

    Nelfinavir is a potent HIV-1 protease inhibitor. It is used in combination with other antiviral drugs in the treatment of HIV in both adults and children.

  6. Drug

    Eldecalcitol

    go.drugbank.com/drugs/DB05295
    Investigational

    Eldecalcitol (ED-71), a vitamin D analog, is a more potent inhibitor of bone resorption than alfacalcidol in an estrogen-deficient rat model of osteoporosis.

    Categories: Vitamins (Fat Soluble)
  7. Drug

    Inebilizumab

    go.drugbank.com/drugs/DB12530
    ApprovedInvestigational

    [L52705,L14315] It is the first and only FDA-approved treatment for IgG4-RD.[L52705] In December 2025, the FDA approved an additional indication for generalized myasthenia gravis. [L54838] … [A214283, A214286] Inebilizumab is a humanized afucosylated monoclonal IgG1 antibody directed against the broadly expressed B-cell surface antigen CD19.

  8. Drug

    NOV-002

    go.drugbank.com/drugs/DB05393
    Investigational

    NOV-002, the lead compound acts as a chemoprotectant and an immunomodulator, in combination with chemotherapy. … It has been administered to over 10,000 patients, demonstrating clinical efficacy and excellent safety data.

  9. Drug

    Efbemalenograstim alfa

    go.drugbank.com/drugs/DB18704
    ApprovedInvestigational

    Efbemalenograstim alfa is a long-acting recombinant fusion protein of granulocyte-colony stimulating factor (G-CSF) due to the addition of the Fc portion of human IgG2, allowing for once-per-cycle administration … [L48852,A262167] As endogenous G-CSF mediates the differentiation of hematopoietic stem cells into granulocytes and eventually neutrophils, the administration of recombinant G-CSF like efbemalenograstim

  10. Drug

    Meplazumab

    go.drugbank.com/drugs/DB16465
    Investigational

    Meplazumab is a humanized anti-CD147 antibody being investigated as an add-on therapy in patients with COVID-19 pneumonia.